Chardan Capital Markets Upgrades Achillion Pharmaceuticals (ACHN) to Neutral Following Underperformance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Leerink Maintains Achillion Pharma (ACHN) at 'Market Perform'; Says MAD Study Questions Raised
November 3, 2016 11:55 AM EDTLeerink affirms Achillion Pharma (NASDAQ: ACHN) at Market Perform following Q3 results and update issued earlier Thursday.
The firm commented today: We believe today's stock weakness is related to caution due to ACHN's disclosure of two cases of liver enzyme elevations in the ongoing multiple ascending dose (MAD) Phase I study of ACH-4471. This update was mentioned... More
Buy Achillion Pharmaceuticals (ACHN) on Sell-Off - Baird
November 3, 2016 11:53 AM EDTBaird analyst Brian Skorney is telling clients to buy Achillion Pharmaceuticals (NASDAQ: ACHN) on today's sell-off. The firm reiterated an Outperform rating and price target of $10.
Skorney commented, "The market for biotech has completely broken down and with it, Achillion's... More
Achillion Pharma (ACHN) Defended at Baird; Analyst Says Selloff Doesn't Make Sense - Bloomberg
November 3, 2016 11:53 AM EDTAchillion Pharma (NASDAQ: ACHN) Defended at Baird; Analyst Says Selloff Doesn't Make Sense - Bloomberg
... MoreAchillion Pharmaceuticals (ACHN) Sell Rating Reiterated at Chardan Capital Markets Amid ACH-4471 Risks
November 3, 2016 11:16 AM EDTChardan Capital Markets analyst Madhu Kumar reiterated a Sell rating and $5 price target on Achillion Pharmaceuticals (NASDAQ: ACHN) saying ACH-4471 liver signals and developmental delays pose risks.
Kumar commented, "This morning, Achillion Pharmaceuticals (Sell) announced 3Q16 earnings results and updates on clinical... More
Achillion Pharma (ACHN) Announces Two Side Effects Observed in MAD Study
November 3, 2016 10:20 AM EDTAchillion Pharma (NASDAQ: ACHN) posted the following with its Q3 press release on Thursday:
Phase I Clinical... More
